Navigation Links
Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
Date:7/18/2012

or 38%.  The increase in costs was due to the increased volume of the TOS business.  Gross margin for TOS was 47% for the years ended April 30, 2012 and 2011.

POS revenues were $2.3 million and $3.4 million for the years ended April 30, 2012 and 2011, respectively, a decrease of $1.1 million, or 31%.  Panel revenue, a component of POS revenue, decreased $1.2 million from the prior year, which is primarily attributable to a decrease in pricing per panel.  Excluding panel revenue, POS revenue was $1.8 million and $1.7 million for the years ended April 30, 2012 and 2011, respectively, an increase of $0.1 million.  During fiscal 2012, the Company experienced significantly higher volumes of implants and drug studies compared to fiscal 2011.  For the year ended April 30, 2012, the Company performed 97 TumorGraft implants, compared to 12 in the prior year.  For the year ended April 30, 2012, the Company completed 19 drug studies, compared to 5 in the prior year.  The increase in volume was offset by decreased pricing for both the TumorGraft implants and drug studies, as part of our strategic decision to accelerate the growth of our Tumorbank.

Cost of POS was $2.4 million and $1.7 million for the years ended April 30, 2012 and 2011, respectively, an increase of $0.7 million, or 42%.  Gross margin for POS was -1% and 51% for the years ended April 30, 2012 and 2011, respectively.  Gross margins declined due to the strategic decision to decrease prices to drive increased volumes.  Additionally, during the second half of fiscal 2012, the Company transitioned its laboratory work in-house from a third-party CRO.  While this has resulted in increased costs during the transition, it is expected to yield future savings.  Finally, costs related to POS studies are expensed as incurred, so expenses include ongoing costs related to 11 drug studies in progress at April 30, 2012.

Research and developmen
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
2. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
3. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
4. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
5. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
6. Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
7. Prosperous Agriculture Reports Outstanding Sales Result for First Half of 2012
8. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012
9. GeneLink Reports First Quarter 2012 Financial Results
10. Genesis Biopharma Mentioned Favorably in BioMedReports Article
11. Vermillion Reports First Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013  Techne Corporation (NASDAQ: ... agreed to acquire 100% ownership of Bionostics Holdings ... Bionostics is a global leader in the development, ... the proper operation of in vitro ... care blood glucose and blood gas testing.  Biosnostics ...
(Date:6/18/2013)... WOODLANDS, Texas , June 18, 2013 /PRNewswire/ ... LXRX ), a biopharmaceutical company focused on discovering ... John Northcott has joined the company ... and operations. Mr. Northcott brings extensive commercial experience ... commercialization across a variety of therapeutic areas. ...
(Date:6/18/2013)... Ontario (PRWEB) June 18, 2013 ... in Proof of Concept and Phase I-IV clinical ... strategic alliance with Northern Air Environmental Technologies (NAET), ... for the deployment, monitoring, and servicing of mobile ... and Ocular clinical trials. , ...
(Date:6/18/2013)... ActiGraph, a leading provider of objective physical ... community, announced today that Dr. Victor KR Matsudo has ... Scientific Director of the Physical Fitness Research Center of ... at Gama Filho University and the Chairman of the ... of Health of São Paulo State, Brazil. , ...
Breaking Biology Technology:Techne Corporation Announces Acquisition Agreement 2Techne Corporation Announces Acquisition Agreement 3Techne Corporation Announces Acquisition Agreement 4Techne Corporation Announces Acquisition Agreement 5John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3Dr. Victor KR Matsudo Joins ActiGraph Scientific Advisory Board 2
... that lets them link up in big biological ... biophysicist and his collaborators. The finding suggests ... energy in part through electrically conducting hairs known ... measurement of electron transport along biological nanowires produced ...
... 11 Generex Biotechnology Corporation (Nasdaq: GNBT ) ... a rights offering of common stock and warrants to its ... reverse stock split at the reconvened special meeting of stockholders ...  The amount of the offering has not been determined, but ...
... Ventures for Global Health (BVGH) announced today that G. ... Company, and James A. Geraghty, Senior Vice President, Genzyme ... addition of these two new board members rounds out ... experience in emerging markets and public-private partnerships. ...
Cached Biology Technology:Microbial hair: It's electric 2Microbial hair: It's electric 3Generex Plans Rights Offering to Stockholders Following Reverse Stock Split 2Generex Plans Rights Offering to Stockholders Following Reverse Stock Split 3Burrill & Company CEO and Genzyme Executive Join BVGH Board of Directors 2Burrill & Company CEO and Genzyme Executive Join BVGH Board of Directors 3
(Date:6/18/2013)... chemical modification of DNA and this modification can ... sequence. Until now, scientists believed that this epigenetic ... Today, a team of researchers from the University ... Louis-Jeantet Professor at the Faculty of Medicine, reveals ... that DNA methylation may play both a passive ...
(Date:6/17/2013)... MA Women in the U.S. exposed to high levels ... likely to have a child with autism as women who ... study from Harvard School of Public Health (HSPH). It is ... and air pollution across the U.S. , "Our findings raise ... the women in our study lived in areas where risk ...
(Date:6/17/2013)... LA JOLLA, CA June 17, 2013 An ... Institute (TSRI), the Howard Hughes Medical Institute and Albert ... a highly promising new anti-tuberculosis compound that attacks the ... findings represent an effort to help solve one of ... of TB and its dangerous drug-resistant strains," said Peter ...
Breaking Biology News(10 mins):The secret of DNA methylation 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4
... partner to watch her weight is not recommended-unless you,re a ... of the Royal Society B . Cleaner fish feed ... While providing this cleaning service, cleaners may get greedy and ... cleaners causes mealtimes to come to an abrupt end as ...
... of stress hormones have the highest mating success and ... new biology research at Queen,s University. "Having high ... to indicate an individual in poor condition who has ... indicates that tree swallows with the highest levels of ...
... Many organic molecules are non-superimposable with their mirror image. The ... can have different properties in biological systems. The problem is ... problem that has proved to be important in the pharmaceutical ... up with a new method to control the process. , ...
Cached Biology News:Fish weight-watchers 2Stress may lead to better bird parenting 2Taming the molecule's Dr. Jekyll and Mr. Hyde 2
Prepared from plasminogen by activation with immobilized human uPA...
Human FADD Affinity Purified Polyclonal Ab...
(3-[125I]iodotyrosyl26)Galanin (porcine), 925 kBq, 25 uCi. Category: IODINE LIGANDS....
... triple quadrupole 1200L sets the new ... environment - incorporating the latest technologies ... liquid chromatography analytical needs. The ... the Transmission Quadrupole Analyzer provide superior ...
Biology Products: